Expression of CRM1 and CDK5 shows high prognostic accuracy for gastric cancer

Table 3 Univariate analysis of the correlation between clinicopathological parameters and survival of patients with gastric cancer

Clinicopathological parameters	Cumulative survival rates (%)		Mean survival time (mo)	Log-rank test	P value
	3 yr	5 yr
Gender
Male	66.1	48.3	49.022	0.092	0.762
Female	56.6	48.0	49.324
Age at surgery (yr)
≤ 60	60.8	48.1	49.510	0.022	0.882
> 60	57.2	47.9	49.285
Size of primary tumor (cm)
≤ 5	84.8	73.4	66.451	44.251	0.0001
> 5	41.1	30.4	37.516
Location of primary tumor
Upper 1/3	51.8	38.7	44.354	28.888	0.0001
Middle 1/3	42.4	33.9	39.508
Lower 1/3	76.5	66.7	61.597
More than 1/3	31.8	22.7	30.500
Borrmann type
Early stage	90.0	90.0	72.186	41.770	0.0001
I + II type	81.9	71.5	64.835
III + IV type	42.6	30.4	38.102
Degree of differentiation
Well/moderate	70.8	60.3	57.397	8.644	0.0031
Poor and not	49.8	39.9	44.056
Lauren’s classification
Intestinal type	66.8	50.7	53.287	0.649	0.420
Diffuse type	56.2	47.4	48.471
Histological type
Papillary	57.1	57.1	50.857	1.026	0.752
Tubular	57.2	47.0	48.339
Mucinous	75.0	53.6	53.850
Signet-ring cell	60.2	48.2	51.110
Depth of invasion
T1	97.5	94.9	78.311	64.970	0.0001
T2	88.9	74.1	67.889
T3	59.2	46.0	48.764
T4	37.8	25.2	34.461
Lymph node metastasis
N0	88.9	80.8	70.120	59.862	0.0001
N1	69.5	69.5	61.079
N2	58.1	34.9	43.674
N3	33.0	23.3	32.911
TNM stage
I	97.7	95.4	78.211	71.616	0.0001
II	76.1	61.3	60.241
III	40.7	29.2	38.186
IV	27.8	16.7	22.518
Vessel invasion
Negative	60.8	49.3	50.492	8.264	0.0041
Positive	20.0	20.0	23.400
Distant metastasis
Negative	60.7	50.6	51.544	20.223	0.0001
Positive	16.7	16.7	22.518
CRM1 expression
Low	54.1	39.7	44.590	7.707	0.0051
High	67.0	61.5	56.540
CDK5 expression
Low	49.5	39.3	53.058	6.234	0.0131
High	63.6	53.4	43.438
CRM1/CDK5 expression
CRM1 and CDK5 Low	47.6	34.3	41.487	13.683	0.0011
CRM1 or CDK5 Low	55.9	45.2	46.873
CRM1 and CDK5 High	73.0	66.7	61.069

¹P < 0.05, statistical significance. CRM: Chromosomal maintenance; CDK: Cyclin-dependent kinase.